About Epygen Biotech
Epygen Biotech is a Healthcare company based in Mumbai (India) founded in 2016. Therapeutic proteins for oncology and cardiovascular disorders are developed. Epygen Biotech has raised $4.55 million across 1 funding round. The company has 47 employees. Its Indian entity Epygen Biotech Private Limited reported revenue of ₹23.61 Cr. Epygen Biotech offers products and services including Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and SARS-CoV-2 Vaccine. Its focus areas include Diversified Pharmaceuticals.
Company details
Epygen Biotech was founded in 2016 in Mumbai, India, within the biotechnology sector. Recombinant enzymes, antibodies, and hormones are developed by the company for oncology, cardiovascular, and immune disorders. The lead candidate, recombinant streptokinase, is targeted at cardiovascular conditions. Additional candidates, such as Peg-filgrastim and Bevacizumab, address cancer treatment, while teriparatide is intended for osteoporosis in postmenopausal women. Operations focus on therapeutic protein development.
- Headquarters Mumbai, India
- Employees 47
- SectorsHealthcare
- Phone•••• ••••
- Website epygenbiotech.com
- Social LinkedIn X Facebook YouTube
- Legal Name Epygen Biotech Private Limited
- Date of Incorporation 25 Aug, 2011
- Jurisdiction Rasayani, Maharashtra, India
- Annual Revenue₹23.61 Cr
FY 2025 · +138% YoY
- Net Profit₹7.02 Cr
FY 2025 · 30% margin
- EBITDA₹14.59 Cr
FY 2025 · 62% margin
- Total Equity Funding$4.55M (USD)
in 1 rounds
- Latest Funding Round$4.55M (USD), Angel Round
Sep 2016
- Employee Count47
Associated legal entities of Epygen Biotech
Epygen Biotech operates through Epygen Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Epygen Biotech Private Limited CIN U24233MH2011PTC221254 | Active | 25 Aug 2011 | Rasayani, Maharashtra | ₹23.6 Cr | 47 | 4 | View details |
Products & Services of Epygen Biotech
Epygen Biotech offers a comprehensive portfolio of products and services, including Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and SARS-CoV-2 Vaccine.
Treats cardiovascular conditions using recombinant technology.
Supports oncology patients by boosting white blood cell production.
Targets tumors for oncology treatment applications.
Manages hormonal disorders through protein-based therapy.
Provides immunity against viral infections like COVID-19.
Offers contract development for biopharmaceutical production needs.
Apps and channels of Epygen Biotech
its YouTube channel Epygen Biotech Pvt Ltd has 26 subscribers and 2 videos.
Videos from Epygen Biotech
The most watched videos on Epygen Biotech's YouTube channel, Epygen Biotech Pvt Ltd (26 subscribers). Click a video to play it here.
More on Epygen Biotech Pvt Ltd.
Funding Insights of Epygen Biotech
Epygen Biotech has successfully raised a total of $4.55M through 1 strategic funding round. The most recent funding activity was a Angel Round of $4.55 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.55M
- Total Rounds 1
- Last Round Angel Round — $4.55M
- First Round $4.55M
(Sep 2016)
All 1 funding rounds of Epygen Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $4.55M | Angel Round | – | – | – |
Board of directors of Epygen Biotech Private Limited (Epygen Biotech)
Epygen Biotech Private Limited is the primary company behind Epygen Biotech. The board of Epygen Biotech Private Limited currently have 4 directors; the longest-serving is Debayan Sukhamoy Ghosh, appointed in 2011. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Debayan Sukhamoy Ghosh DIN 03591159 | Director | 25 Aug 2011 | 15 yrs 2 mo | Epygen Biotech Private Limited |
| Ineeyan Vivekanandan Ariyaratnam DIN 03596235 | Director | 25 Aug 2011 | 15 yrs 2 mo | Epygen Biotech Private Limited |
| Manickam DIN 07179240 | Director | 11 Jul 2016 | 10 yrs 3 mo | Epygen Biotech Private Limited |
| Soumitro Deb DIN 08720030 | Director | 18 Mar 2020 | 6 yrs 7 mo | Epygen Biotech Private Limited |
Financials of Epygen Biotech
Figures of Epygen Biotech Private Limited, the primary company behind Epygen Biotech, for FY 2025. Revenue was ₹23.61 Cr (+138% year on year). Net profit was ₹7.02 Cr (30% margin). EBITDA was ₹14.59 Cr (62% margin). Revenue has grown at a compounded annual rate of +106% over three years and +62% over five years.
- ₹23.61 CrRevenue · FY 2025 · +138% YoY
- ₹7.02 CrNet profit · 30% margin
- ₹14.59 CrEBITDA · 62% margin
- ₹14.96 CrPaid-up capital
- 47Employees (provident fund records)
- +106%Revenue CAGR, 3 years
- +62%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Epygen Biotech Private Limited are on its company page.
Detailed financial statements for Epygen Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Epygen Biotech
2 dated milestones of Epygen Biotech, from founding to its latest funding, stage changes and deals.
- Founded Epygen Biotech is founded.
- Funding First funding round of $4.6M.
Web traffic of Epygen Biotech
Websites that share an audience with Epygen Biotech (epygenbiotech.com).
Websites whose visitors overlap most with Epygen Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
flagshipbiotech.com | flagshipbiotech.com | 100% | #10,435,616 | – | |
| bio-tech.co.in | 100% | View details | |||
| rapturebio.com | 98% | 10.9K | #2,205,064 | View details | |
| zytex.com | 92% | 1.3K | #9,998,407 | View details | |
| anazeal.com | 85% | 1.5K | #10,817,506 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Epygen Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epygen Biotech
Complete news archive for Epygen Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epygen Biotech
Epygen Biotech was founded in 2016.
Epygen Biotech is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Epygen Biotech is a funded company, having raised a total of $4.55M across 1 funding round to date. The company's 1st funding round was a Angel Round of $4.55M, raised on Sep 2016.
Epygen Biotech has 47 employees.
The primary company behind Epygen Biotech, Epygen Biotech Private Limited, reported revenue of ₹23.61 Cr for FY 2025, up 138% year on year.
Epygen Biotech was founded in 2016 in Mumbai, India, within the biotechnology sector. Recombinant enzymes, antibodies, and hormones are developed by the company for oncology, cardiovascular, and immune disorders. The lead candidate, recombinant streptokinase, is targeted at cardiovascular conditions. Additional candidates, such as Peg-filgrastim and Bevacizumab, address cancer treatment, while teriparatide is intended for osteoporosis in postmenopausal women. Operations focus on therapeutic protein development.
Epygen Biotech offers Recombinant Streptokinase, Pegfilgrastim, Bevacizumab, Teriparatide, and 2 more products and services.
Epygen Biotech operates through Epygen Biotech Private Limited.
The legal entities of Epygen Biotech currently have 4 directors, including Debayan Sukhamoy Ghosh, Ineeyan Vivekanandan Ariyaratnam, Soumitro Deb and others.